JNJ’s spine market position
Johnson & Johnson (JNJ) registered sales of $804 million in the first quarter of fiscal 2018, representing a YoY (year-over-year) fall of 8.9%. The spine business has been witnessing declining sales recently due to gaps in the company’s product portfolio sales force attrition and a slowdown in the US spine market.
Though JNJ has launched a number of products, established partnerships, and undertaken acquisitions aimed at filling its spine business portfolio gaps, it’s not satisfied with its performance. In the spine market, JNJ is the second-largest player globally and the leading player in key markets such as China and the EMEA (Europe, the Middle East, and Africa) region.
JNJ’s spine segment growth strategy
Johnson & Johnson is focused on making internal and external investments in high-growth areas, including the minimally invasive solutions, complex cervical pathology, deformity, and aging spine businesses. The company has recently launched a complete platform that includes the VIPER PRIME pedicle screw system, the Concorde lift expandable cage, and the Concorde clear MIS Discectomy device, which is designed to deliver more efficient, simplified, and faster spinal fusion surgery.
The company has also recently entered into a partnership with Prosidyan for the promotion of a line of synthetic bone materials manufactured by Prosidyan that enables optimal absorption and ease of use during spinal fusion surgery.
In the interbody business, JNJ has recently launched the PROTI 360 devices family. The company also plans to launch Sentio later this year. Sentio is the only software-enabled solution in the market used for nerve localization.
In the next article, we’ll take a look at JNJ’s surgery business growth strategy.